Search

Displaying results 2981 - 2990 of 10000 in total
  1. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

  2. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    [A178102] In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. [A178105, A178108] … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.

  3. Drug

    Coagulation Factor IX Human

    go.drugbank.com/drugs/DB13152
    ApprovedInvestigational

    Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.

    Products: Aımafıx 500 IU/10 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, Aımafıx 1000 IU/10 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET
  4. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    Early intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN. … for the treatment of adult patients with active lupus nephritis.

  5. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

  6. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555] … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

  7. Drug

    Meglumine

    go.drugbank.com/drugs/DB09415
    ApprovedInvestigational

    Mixtures: UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 100 ML, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 ML
  8. Target

    P2Y purinoceptor 2

    go.drugbank.com/bio_entities/BE0002401
    TargetHumans

    Receptor for ATP and UTP coupled to G proteins that activate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP

    Synonyms: ATP receptor, P2U receptor 1Function: A1 adenosine receptor binding
  9. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.

    Categories: Androgen Receptor Inhibitors
  10. Drug

    Terconazole

    go.drugbank.com/drugs/DB00251
    Approved

    [A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole. … [A178096] Terconazole was initially approved by the FDA in 1987.

    Products: FUNGISTAT OVULOS DE 80 MG., FUNGISTAT CREMA VAGINAL DE 0.8%